January 16, 2018

Manus Bio awarded funding to develop novel production method for Artemisinin

Manus Bio

CAMBRIDGE, Mass., Jan. 11, 2018 – Manus Bio Inc. (Manus Bio), a company which produces complex natural products through advanced fermentation, announced today that it has received funding from the Bill & Melinda Gates Foundation for the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria. Manus Bio will use its proprietary microbial chassis and unique enzyme engineering approaches to develop an advanced fermentation process for low-cost manufacturing of artemisinin.

About Manus Bio

Manus Bio is a global leader in the use of advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The core team and technology are from MIT, and the company is headquartered in Cambridge, MA, USA. For more information, visit www.manusbio.com.


Stay Updated on the Latest News in Synthetic Biology

Subscribe to the Weekly SynBioBeta Digest


Stay updated on the latest news in synthetic biology

Subscribe to the SynBioBeta news digest